Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
PLoS Pathog ; 17(5): e1009553, 2021 05.
Article in English | MEDLINE | ID: mdl-34015044

ABSTRACT

Bacterial infection results in a veritable cascade of host responses, both local and systemic. To study the initial stages of host-pathogen interaction in living tissue we use spatially-temporally controlled in vivo models. Using this approach, we show here that within 4 h of a uropathogenic Escherichia coli (UPEC) infection in the kidney, an IFNγ response is triggered in the spleen. This rapid infection-mediated inter-organ communication was found to be transmitted via nerve signalling. Bacterial expression of the toxin α-hemolysin directly and indirectly activated sensory neurons, which were identified in the basement membrane of renal tubules. Nerve activation was transmitted via the splenic nerve, inducing upregulation of IFNγ in the marginal zones of the spleen that led to increasing concentrations of IFNγ in the circulation. We found that IFNγ modulated the inflammatory signalling generated by renal epithelia cells in response to UPEC infection. This demonstrates a new concept in the host response to kidney infection; the role of nerves in sensing infection and rapidly triggering a systemic response which can modulate inflammation at the site of infection. The interplay between the nervous and immune systems is an exciting, developing field with the appealing prospect of non-pharmaceutical interventions. Our study identifies an important role for systemic neuro-immune communication in modulating inflammation during the very first hours of a local bacterial infection in vivo.


Subject(s)
Escherichia coli Infections/complications , Host-Pathogen Interactions , Inflammation/pathology , Interferon-gamma/metabolism , Kidney/microbiology , Neuroimmunomodulation , Spleen/metabolism , Animals , Epithelial Cells/microbiology , Inflammation/etiology , Inflammation/metabolism , Male , Rats , Rats, Sprague-Dawley , Uropathogenic Escherichia coli/physiology
2.
J Exp Med ; 216(8): 1904-1924, 2019 08 05.
Article in English | MEDLINE | ID: mdl-31196979

ABSTRACT

Rheumatoid arthritis-associated joint pain is frequently observed independent of disease activity, suggesting unidentified pain mechanisms. We demonstrate that antibodies binding to cartilage, specific for collagen type II (CII) or cartilage oligomeric matrix protein (COMP), elicit mechanical hypersensitivity in mice, uncoupled from visual, histological and molecular indications of inflammation. Cartilage antibody-induced pain-like behavior does not depend on complement activation or joint inflammation, but instead on tissue antigen recognition and local immune complex (IC) formation. smFISH and IHC suggest that neuronal Fcgr1 and Fcgr2b mRNA are transported to peripheral ends of primary afferents. CII-ICs directly activate cultured WT but not FcRγ chain-deficient DRG neurons. In line with this observation, CII-IC does not induce mechanical hypersensitivity in FcRγ chain-deficient mice. Furthermore, injection of CII antibodies does not generate pain-like behavior in FcRγ chain-deficient mice or mice lacking activating FcγRs in neurons. In summary, this study defines functional coupling between autoantibodies and pain transmission that may facilitate the development of new disease-relevant pain therapeutics.


Subject(s)
Antibodies, Monoclonal/immunology , Antigen-Antibody Complex/metabolism , Arthralgia/immunology , Arthritis, Rheumatoid/immunology , Autoantibodies/immunology , Cartilage/immunology , Neurons/metabolism , Animals , Antibodies, Monoclonal/therapeutic use , Arthralgia/drug therapy , Arthritis, Rheumatoid/drug therapy , Autoantibodies/therapeutic use , Behavior, Animal/drug effects , Cartilage Oligomeric Matrix Protein/immunology , Collagen Type II/immunology , Disease Models, Animal , Female , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Receptors, IgG/deficiency , Receptors, IgG/genetics
3.
Basic Res Cardiol ; 111(3): 34, 2016 May.
Article in English | MEDLINE | ID: mdl-27071401

ABSTRACT

The inorganic anion nitrate (NO3 (-)), which is naturally enriched in certain vegetables (e.g., spinach and beetroot), has emerged as a dietary component that can regulate diverse bodily functions, including blood pressure, mitochondrial efficiency, and skeletal muscle force. It is not known if dietary nitrate improves cardiac contractility. To test this, mice were supplemented for 1-2 weeks with sodium nitrate in the drinking water at a dose similar to a green diet. The hearts from nitrate-treated mice showed increased left ventricular pressure and peak rate of pressure development as measured with the Langendorff heart technique. Cardiomyocytes from hearts of nitrate-treated and control animals were incubated with the fluorescent indicator Fluo-3 to measure cytoplasmic free [Ca(2+)] and fractional shortening. Cardiomyocytes from nitrate-treated mice displayed increased fractional shortening, which was linked to larger Ca(2+) transients. Moreover, nitrate hearts displayed increased protein expression of the L-type Ca(2+) channel/dihydropyridine receptor and peak L-type Ca(2+) channel currents. The nitrate-treated hearts displayed increased concentration of cAMP but unchanged levels of cGMP compared with controls. These findings provide the first evidence that dietary nitrate can affect the expression of important Ca(2+) handling proteins in the heart, resulting in increased cardiomyocyte Ca(2+) signaling and improved left ventricular contractile function. Our observation shows that dietary nitrate impacts cardiac function and adds understanding to inorganic nitrate as a physiological modulator.


Subject(s)
Calcium Signaling/physiology , Heart/drug effects , Heart/physiology , Myocardial Contraction/drug effects , Nitrates/pharmacology , Animals , Blotting, Western , Diet , Isolated Heart Preparation , Male , Mice , Mice, Inbred C57BL , Myocardial Contraction/physiology , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/physiology , Patch-Clamp Techniques
4.
Pain Manag ; 6(3): 265-84, 2016.
Article in English | MEDLINE | ID: mdl-27086843

ABSTRACT

Pain is one of the most challenging symptoms for patients with rheumatoid arthritis (RA). RA-related pain is frequently considered to be solely a consequence of inflammation in the joints; however, recent studies show that multiple mechanisms are involved. Indeed, RA pain may start even before the disease manifests, and frequently does not correlate with the degree of inflammation or pharmacological management. In this aspect, animal studies have the potential to provide new insights into the pathology that initiate and maintain pain in RA. The focus of this review is to describe the most commonly used animal models for studies of RA pathology, which have also been utilized in pain research, and to summarize findings providing potential clues to the mechanisms involved in the regulation of RA-induced pain.


Subject(s)
Arthritis, Rheumatoid/complications , Disease Models, Animal , Pain/physiopathology , Animals , Humans , Inflammation Mediators/metabolism , Pain/etiology , Pain/metabolism , Spinal Cord/metabolism , Spinal Cord/physiopathology
5.
Ann Rheum Dis ; 75(4): 730-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26613766

ABSTRACT

OBJECTIVE: An interesting and so far unexplained feature of chronic pain in autoimmune disease is the frequent disconnect between pain and inflammation. This is illustrated well in rheumatoid arthritis (RA) where pain in joints (arthralgia) may precede joint inflammation and persist even after successful anti-inflammatory treatment. In the present study, we have addressed the possibility that autoantibodies against citrullinated proteins (ACPA), present in RA, may be directly responsible for the induction of pain, independent of inflammation. METHODS: Antibodies purified from human patients with RA, healthy donors and murinised monoclonal ACPA were injected into mice. Pain-like behaviour was monitored for up to 28 days, and tissues were analysed for signs of pathology. Mouse osteoclasts were cultured and stimulated with antibodies, and supernatants analysed for release of factors. Mice were treated with CXCR1/2 (interleukin (IL) 8 receptor) antagonist reparixin. RESULTS: Mice injected with either human or murinised ACPA developed long-lasting pronounced pain-like behaviour in the absence of inflammation, while non-ACPA IgG from patients with RA or control monoclonal IgG were without pronociceptive effect. This effect was coupled to ACPA-mediated activation of osteoclasts and release of the nociceptive chemokine CXCL1 (analogue to human IL-8). ACPA-induced pain-like behaviour was reversed with reparixin. CONCLUSIONS: The data suggest that CXCL1/IL-8, released from osteoclasts in an autoantibody-dependent manner, produces pain by activating sensory neurons. The identification of this new pain pathway may open new avenues for pain treatment in RA and also in other painful diseases associated with autoantibody production and/or osteoclast activation.


Subject(s)
Arthralgia/immunology , Autoantibodies/immunology , Chemokine CXCL1/immunology , Citrulline/immunology , Interleukin-8/immunology , Nociception/physiology , Osteoclasts/immunology , Animals , Autoantibodies/pharmacology , Behavior, Animal/drug effects , Case-Control Studies , Chemokine CXCL1/drug effects , Chemokines , Inflammation , Interleukin-8/drug effects , Male , Mice , Mice, Inbred BALB C , Nociception/drug effects , Osteoclasts/drug effects , Receptors, Interleukin-8/antagonists & inhibitors , Sulfonamides/pharmacology
6.
Pharmacol Biochem Behav ; 122: 1-6, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24582849

ABSTRACT

It has been shown that imipramine, a tricyclic antidepressant (TCA), is a potent analgesic agent. However, the effect of imipramine on visceral pain has not been extensively investigated. In the current study, our aim was to characterise the putative analgesic effect of intravenous imipramine on visceral pain in rats. Our second aim was to assess the involvement of serotonergic (5-HT2,3,4) and noradrenergic (α(2A, 2B, 2C)) receptor subtypes in this putative antinociceptive effect of imipramine. Male Sprague Dawley rats (250-300 g) were implanted with venous catheters for drug administration and implanted with enamelled nichrome electrodes for electromyography of the external oblique muscles. Noxious visceral stimulation was applied via by colorectal distension (CRD). The visceromotor responses (VMRs) to CRD were quantified electromyographically before and after imipramine administration at 5, 15, 30, 60, 90 and 120 min. In the antagonist groups, the agents were administered 10 min before imipramine. The administration of imipramine (5-40 mg/kg) produced a dose-dependent reduction in VMR. The administration of yohimbine (a nonselective α2-adrenoceptor antagonist, 1 mg/kg), BRL-44408 (an α(2A)-adrenoceptor antagonist, 1 mg/kg) or MK-912 (an α2C-adrenoceptor antagonist, 300 µg/kg) but not imiloxan (an α(2B)-adrenoceptor antagonist, 1 mg/kg) inhibited the antinociceptive effect of imipramine (20 mg/kg). Additionally, ketanserin (a 5-HT2 receptor antagonist, 0.5, 1, and 2 mg/kg) and GR113808 (a 5-HT4 receptor antagonist, 1 mg/kg) enhanced, and ondansetron (a 5-HT3 receptor antagonist, 0.5, 1, and 2 mg/kg) failed to alter the imipramine-induced antinociceptive effect. Our data demonstrated that, in the CDR-induced rat visceral pain model, intravenous imipramine appeared to have antinociceptive potential and that α(2A)-/α(2C)-adrenoceptors and 5-HT2/5-HT4 receptors may be responsible for the antinociceptive effect of imipramine on visceral pain in rats.


Subject(s)
Analgesics/administration & dosage , Imipramine/administration & dosage , Receptors, Adrenergic, alpha-2/physiology , Receptors, Serotonin, 5-HT2/physiology , Receptors, Serotonin, 5-HT4/physiology , Visceral Pain/drug therapy , Administration, Intravenous , Adrenergic alpha-2 Receptor Antagonists/pharmacology , Animals , Colon/pathology , Dose-Response Relationship, Drug , Male , Pain Measurement/drug effects , Pain Measurement/methods , Rats , Rats, Sprague-Dawley , Rectum/pathology , Serotonin Antagonists/pharmacology , Treatment Outcome , Visceral Pain/pathology
7.
PLoS One ; 8(9): e75543, 2013.
Article in English | MEDLINE | ID: mdl-24086560

ABSTRACT

Lipoxins and resolvins have anti-inflammatory and pro-resolving actions and accumulating evidence indicates that these lipid mediators also attenuate pain-like behavior in a number of experimental models of inflammation and tissue injury-induced pain. The present study was undertaken to assess if spinal administration of lipoxin A4 (LXA4) or 17 (R)-resolvin D1 (17(R)-RvD1) attenuates mechanical hypersensitivity in the carrageenan model of peripheral inflammation in the rat. Given the emerging role of spinal cytokines in the generation and maintenance of inflammatory pain we measured cytokine levels in the cerebrospinal fluid (CSF) after LXA4 or 17(R)-RvD1 administration, and the ability of these lipid metabolites to prevent stimuli-induced release of cytokines from cultured primary spinal astrocytes. We found that intrathecal bolus injection of LXA4 and17(R)-RvD1 attenuated inflammation-induced mechanical hypersensitivity without reducing the local inflammation. Furthermore, both LXA4 and 17(R)-RvD1 reduced carrageenan-induced tumor necrosis factor (TNF) release in the CSF, while only 17(R)-RvD1attenuated LPS and IFN-γ-induced TNF release in astrocyte cell culture. In conclusion, this study demonstrates that lipoxins and resolvins potently suppress inflammation-induced mechanical hypersensitivity, possibly by attenuating cytokine release from spinal astrocytes. The inhibitory effect of lipoxins and resolvins on spinal nociceptive processing puts them in an intriguing position in the search for novel pain therapeutics.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Docosahexaenoic Acids/pharmacology , Hypersensitivity/drug therapy , Inflammation/drug therapy , Lipoxins/pharmacology , Spinal Cord/drug effects , Adaptor Proteins, Signal Transducing/metabolism , Animals , Astrocytes/drug effects , Astrocytes/metabolism , Cells, Cultured , Cytokines/metabolism , Edema/drug therapy , Edema/metabolism , Humans , Hypersensitivity/metabolism , Inflammation/metabolism , Interferon-gamma/metabolism , Male , Mitogen-Activated Protein Kinases/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Lipoxin/metabolism , Spinal Cord/metabolism , Tumor Necrosis Factor-alpha/metabolism
8.
Acta Cardiol ; 68(3): 291-7, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23882875

ABSTRACT

OBJECTIVE: Both computed tomography (CTA) and conventional angiography (CCA) can provide direct visualization of the coronary arteries. The aim of the present study was to compare the radiation exposure between CTA and CCA and to search whether this amount of radiation causes significant DNA damage. METHOD: Seventy-two patients who underwent CTA or CCA were enrolled prospectively. We recorded the radiation dosage that was used during the procedures and calculated the effective dose (ED). We determined the sister chromatid exchange (SCE) level from the blood samples which were drawn from the patients before and after the procedures. The change in SCE is used as the measure of DNA damage induced by the radiation. RESULTS: The patients in the CTA (n = 36) and CCA groups (n= 36) had similar baseline characteristics. The ED was higher in CTA examinations compared to CCA examinations (14.2 +/- 2.7 vs 6.4 +/- 3.1, P <0.001). The SCE level increased significantly after both angiography methods (P <0.001). When the change in SCE after angiography was compared, we did not find a significant difference among the groups (2.73 +/- 1.6 vs 2.54 +/- 1.22, P= NS). CONCLUSION: Although the patients who underwent CTA were exposed to a greater amount of radiation, the radiation-induced genetic damage was similar with both types of the procedures.


Subject(s)
Angina, Stable/diagnostic imaging , Coronary Angiography/adverse effects , DNA Damage/genetics , DNA/radiation effects , Multidetector Computed Tomography/adverse effects , Radiation Injuries/genetics , Angina, Stable/blood , Coronary Angiography/methods , Dose-Response Relationship, Radiation , Female , Humans , Male , Middle Aged , Prospective Studies , Radiation Injuries/diagnosis , Radiation Injuries/etiology , Sister Chromatid Exchange/genetics , Sister Chromatid Exchange/radiation effects
9.
J Neurosci Res ; 91(2): 300-12, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23184810

ABSTRACT

Astrocyte activation is an important feature in many disorders of the central nervous system, including chronic pain conditions. Activation of astrocytes is characterized by a change in morphology, including hypertrophy and increased size of processes, proliferation, and an increased production of proinflammatory mediators. The xanthine derivatives pentoxifylline and propentofylline are commonly used experimentally as glial inhibitors. These compounds are generally believed to attenuate glial activity by raising cyclic AMP (cAMP) levels and inhibiting glial tumor necrosis factor (TNF) production. In the present study, we show that these substances inhibit TNF and serum-induced astrocyte proliferation and signaling through the mammalian target of rapamycin (mTOR) pathway, demonstrated by decreased levels of phosphorylated S6 kinase (S6K), commonly used as a marker of mTOR complex (mTORC) activation. Furthermore, we show that pentoxifylline and propentofylline also inhibit JNK and p38, but not ERK, activation induced by TNF. In addition, the JNK antagonist SP600125, but not the p38 inhibitor SB203580, prevents TNF-induced activation of S6 kinase, suggesting that pentoxifylline and propentofylline may regulate mTORC activity in spinal astrocytes partially through inhibition of the JNK pathway. Our results suggest that pentoxifylline and propentofylline inhibit astrocyte activity in a broad fashion by attenuating flux through specific pathways.


Subject(s)
Astrocytes/drug effects , Cell Proliferation/drug effects , Mitogen-Activated Protein Kinases/metabolism , Neuroprotective Agents/pharmacology , Pentoxifylline/pharmacology , Sirolimus/metabolism , Xanthines/pharmacology , Animals , Cells, Cultured , Cyclic AMP/metabolism , Enzyme Inhibitors/pharmacology , Male , Nerve Tissue Proteins/metabolism , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Spinal Cord/cytology , Time Factors , Tumor Necrosis Factor-alpha/metabolism
10.
Arthritis Rheum ; 64(12): 3886-96, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22933386

ABSTRACT

OBJECTIVE: Pain is one of the most debilitating symptoms reported by rheumatoid arthritis (RA) patients. While the collagen antibody-induced arthritis (CAIA) model is used for studying the effector phase of RA pathologic progression, it has not been evaluated as a model for studies of pain. Thus, this study was undertaken to examine pain-like behavior induced by anticollagen antibodies and to assess the effect of currently prescribed analgesics for RA. In addition, the involvement of spinal glia in antibody-induced pain was explored. METHODS: CAIA was induced in mice by intravenous injection of a collagen antibody cocktail, followed by intraperitoneal injection of lipopolysaccharide. Disease severity was assessed by visual and histologic examination. Pain-like behavior and the antinociceptive effect of diclofenac, buprenorphine, gabapentin, pentoxifylline, and JNK-interacting protein 1 were examined in mechanical stimulation experiments. Spinal astrocyte and microglia reactivity were investigated by real-time polymerase chain reaction and immunohistochemistry. RESULTS: Following the induction of CAIA, mice developed transient joint inflammation. In contrast, pain-like behavior was observed prior to, and outlasted, the visual signs of arthritis. Whereas gabapentin and buprenorphine attenuated mechanical hypersensitivity during both the inflammatory and postinflammatory phases of arthritis, diclofenac was antinociceptive only during the inflammatory phase. Spinal astrocytes and microglia displayed time-dependent signs of activation, and inhibition of glial activity reversed CAIA-induced mechanical hypersensitivity. CONCLUSION: CAIA represents a multifaceted model for studies exploring the mechanisms of pain induced by inflammation in the articular joint. Our findings of a time-dependent prostaglandin and spinal glial contribution to antibody-induced pain highlight the importance of using appropriate disease models to assess joint-related pain.


Subject(s)
Arthralgia/etiology , Arthritis, Experimental/complications , Neuroglia/pathology , Prostaglandins/metabolism , Spine/pathology , Amines/therapeutic use , Analgesics/therapeutic use , Animals , Arthralgia/drug therapy , Arthralgia/metabolism , Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Buprenorphine/therapeutic use , Cyclohexanecarboxylic Acids/therapeutic use , Diclofenac/therapeutic use , Disease Models, Animal , Gabapentin , Male , Mice , Mice, Inbred BALB C , Mice, Inbred CBA , Neuroglia/metabolism , Spine/metabolism , Time Factors , Treatment Outcome , gamma-Aminobutyric Acid/therapeutic use
11.
Coron Artery Dis ; 22(5): 333-8, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21558855

ABSTRACT

INTRODUCTION: Inflammation and polymorphonuclear neutrophils are shown to be important in the pathogenesis of acute myocardial infarction (AMI). Neutrophil gelatinase-associated lipocalin (NGAL) is secreted from neutrophils and may increase the proteolytic activity within the atherosclerotic plaque. We aimed to investigate whether the plasma levels of NGAL are higher in patients with AMI compared with stable coronary artery disease (CAD). METHODS: The study population consisted of 128 eligible patients who underwent coronary angiography with the clinical diagnosis of CAD. Of the 128 patients included in the study, the diagnosis was ST-segment elevation myocardial infarction (STEMI) in 53 patients, non-ST-elevation myocardial infarction (NSTEMI) in 38 patients and stable CAD in 37 patients. Plasma level of NGAL was measured in all patients with an enzyme-linked immunosorbent assay method. We compared the plasma NGAL levels among the groups. RESULTS: We found higher plasma NGAL levels in patients with AMI compared with the patients with stable CAD (146 ± 23 vs. 101 ± 53 ng/ml, P<0.001). The plasma NGAL levels between the subgroups of AMI were similar (145 ± 23.9 vs. 145 ± 23.4 ng/ml, P=not significant). In multivariate analysis, the independent factors related to AMI were current smoking (P=0.024), extent and severity of coronary atherosclerosis (P=0.030), and NGAL levels. The plasma NGAL level was independently related to the existence of AMI (odds ratio: 1.045, 95% confidence interval: 1.019-1.072, P=0.001). In patients with plasma NGAL level above 127 ng/ml, we observed a 12 times higher incidence of AMI (odds ratio: 12.2, 95% confidence interval: 2.3-64, P=0.003). CONCLUSION: The plasma level of NGAL is higher in patients with AMI compared with the patients with stable CAD. This finding may suggest an active pathophysiological role for NGAL in development of acute coronary events.


Subject(s)
Coronary Artery Disease/blood , Lipocalins/blood , Myocardial Infarction/blood , Proto-Oncogene Proteins/blood , Acute-Phase Proteins , Aged , Coronary Angiography , Electrocardiography , Enzyme-Linked Immunosorbent Assay , Female , Humans , Lipocalin-2 , Male , Middle Aged
12.
Hum Exp Toxicol ; 30(2): 124-8, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20375122

ABSTRACT

Acute carbon monoxide (CO) poisoning can cause early and persistent damages in tissues sensitive to hypoxia. This study investigated serum heart-type fatty acid-binding protein (H-FABP) levels as a biomarker of acute CO poisoning in rats. The rats were exposed to a mixture of either 3000 (group A) or 5000 (group B) parts per million (ppm) CO in air, or to ambient air (group C, control group). Blood samples were taken just before, immediately after and 6 hours after the exposure, and serum H-FABP and troponin-I levels were measured. The consciousness level was evaluated just after the exposure. The survival rate was monitored for 7 days. Serum H-FABP levels increased just after the CO exposure in both groups A and B. Additionally, H-FABP level was higher in group B than in group A, immediately after the exposure. However, serum troponin-I levels only increased at 6 hours after the CO exposure in groups A and B. Consciousness and survival rates in group B were lower than that in group A. Our results suggest that H-FABP might have potential to be an early and quantitative parameter of clinical severity and prognosis in CO poisoning.


Subject(s)
Carbon Monoxide Poisoning/blood , Fatty Acid-Binding Proteins/blood , Animals , Biomarkers/blood , Carbon Monoxide Poisoning/diagnosis , Carboxyhemoglobin/analysis , Disease Models, Animal , Fatty Acid Binding Protein 3 , Male , Prognosis , Rats , Rats, Sprague-Dawley , Troponin I/blood
13.
Brain Dev ; 32(5): 396-403, 2010 May.
Article in English | MEDLINE | ID: mdl-19500926

ABSTRACT

PURPOSE: We aimed to establish the physical, motor, and cognitive teratogenic effect of levetiracetam exposure throughout pregnancy in rats. METHODS: Thirty-two Sprague-Dawley pregnant female rats were divided into four groups. Groups 1-3 were treated with different doses of levetiracetam (25, 50, 100 mg/kg/d) from gestational days 1 to 18. Group 4 (control group) was treated with the same volume of saline. The day of occurrence for pinna detachment, incisor eruption, eye opening, ear opening, and fur development were also monitored. Righting reflex, negative geotaxis, and grip response were evaluated as measures of the development of reflexes. The cognitive and motor developments were established with T-maze, holeboard, Y-maze, locomotor activity, and passive avoidance test. RESULTS: Levetiracetam exposure at 25, 50 and 100 mg/kg/d doses did not affect the timing of physical landmark developments. The dose of 100 mg/kg/d resulted in a significant delay in reaction time of the surface righting reflex compared to the control group. Two higher dose groups (50 and 100 mg/kg/d) had delay in the appearance of negative geotaxis reflex compared to the control group. Both groups maternally exposed to 50 and 100 mg/kg/d had a lower percentage of grip strength response comparing to control group on the first day of testing. On the second test day, only pups prenatally exposed to 100 mg/kg/d levetiracetam persistently had a significantly lower percentage of response. We could not find a significant difference between groups in tests for the locomotor activity, memory, and learning (T- and Y-maze, passive avoidance test), and explorative behavior (holeboard tests). CONCLUSION: We showed that levetiracetam had only a transient impact on reflex maturation and no impact on physical and cognitive function in offspring of rats exposed to the drug during pregnancy. Levetiracetam may become a promising candidate for the treatment of epileptic women in pregnancy.


Subject(s)
Anticonvulsants/pharmacology , Cognition/drug effects , Motor Activity/drug effects , Piracetam/analogs & derivatives , Prenatal Exposure Delayed Effects , Animals , Avoidance Learning/drug effects , Exploratory Behavior/drug effects , Female , Learning/drug effects , Levetiracetam , Male , Piracetam/pharmacology , Pregnancy , Psychomotor Performance/drug effects , Rats , Rats, Sprague-Dawley
14.
Int J Neurosci ; 119(10): 1705-17, 2009.
Article in English | MEDLINE | ID: mdl-19922382

ABSTRACT

In the present study we investigated the effects of mixed imidazoline-1 and alpha(2)-adrenoceptor agonist, moxonidine, in glutamate-induced neurotoxicity in frontal cortical cell cultures of rat pups by dye exclusion test. Also, phosphorylated p38 mitogen activated protein kinases (p-p38 MAPK) levels were determined from rat frontal cortical tissue homogenates by two dimensional gel electrophoresis and semidry western blotting. Glutamate at a concentration of 10(-6) M was found neurotoxic when applied for 16 hr in cell cultures. Dead cell mean scores were 12.8 +/- 0.5 for control and 52.3 +/- 4.8 for glutamate (p < .001). On the other hand, p-p38 MAPK levels start to increase at a glutamate concentration of 10(-7) M for 20 min application. Moxonidine was found to have an U-shape neuroprotective effect in glutamate-induced neurotoxicity in neuronal cell culture experiments. Even though moxonidine did not induce neurotoxicity alone between the doses of 10(-8) to 10(-4) M concentrations in cell culture series, it caused the reduction of glutamate-induced dead cell population 23.07 +/- 3.6% in 10(-6) M and 26.7 +/- 2.1% in 10(-5) M concentrations (p <.001 for both, in respect to control values). The protective effect of moxonidine was confirmed in 10(-8) and 10(-7) M, but not in higher concentrations in glutamate neurotoxicity in gel electrophoresis and western blotting of p-p38 MAPK levels. In addition to other studies that revealed an antihypertensive feature of moxonidine, we demonstrated a possible partial neuroprotective role in lower doses for it in glutamate-mediated neurotoxicity model.


Subject(s)
Imidazoles/pharmacology , Imidazoles/therapeutic use , Imidazoline Receptors/agonists , Neurons/drug effects , Neuroprotective Agents/pharmacology , Neurotoxicity Syndromes , Animals , Animals, Newborn , Cell Count/methods , Cells, Cultured , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Interactions , Frontal Lobe/cytology , Gene Expression Regulation, Enzymologic/drug effects , Glutamic Acid/toxicity , Neuroprotective Agents/therapeutic use , Neurotoxicity Syndromes/drug therapy , Neurotoxicity Syndromes/enzymology , Neurotoxicity Syndromes/etiology , Rats , Rats, Sprague-Dawley , p38 Mitogen-Activated Protein Kinases/metabolism
15.
Pharmacol Rep ; 60(6): 872-9, 2008.
Article in English | MEDLINE | ID: mdl-19211979

ABSTRACT

Serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors represent important targets for the development of new treatments for detrusor overactivity and urinary incontinence. The present study was undertaken to investigate the effects of the forced swimming test (FST) on the contractile response of isolated rat detrusor muscle and to examine the effects of in vivo treatments of fluoxetine and sertraline on altered detrusor muscle contractility. Fluoxetine (20 mg/kg ip) and sertraline (10 mg/kg ip) were administered once a day for 14 days. Rats were exposed to the FST on the 15th day. After the test, detrusor muscles were removed and placed in organ baths, and the contraction responses induced by carbachol, potassium chloride (KCl) and electrical field stimulation (EFS) were recorded. The contractile responses of detrusor muscle strips to carbachol and electrical field stimulation were found to be increased at all carbachol doses and frequencies, respectively. FST also increased the contractile responses to KCl, which is used to test the differences in postreceptor-mediated contractions. The hypercontractile responses of detrusor strips to carbachol, EFS and KCl were abolished by treatment with both fluoxetine and sertraline. These treatments also decreased the immobility duration in the FST consistent with an antidepressant-like effect in this test. The results of this study provide the first evidence that FST increases contractility of the rat detrusor muscle, and this hypercontractility was abolished by chronic treatments of fluoxetine and sertraline at antidepressant doses by decreasing the postreceptor-mediated events.


Subject(s)
Antidepressive Agents/pharmacology , Depression/physiopathology , Fluoxetine/pharmacology , Muscle Contraction/drug effects , Sertraline/pharmacology , Urinary Bladder/drug effects , Animals , Calcium Channels/physiology , Carbachol/pharmacology , Electric Stimulation , Male , Motor Activity/drug effects , Potassium Chloride/pharmacology , Rats , Rats, Wistar , Swimming , Urinary Bladder/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...